Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
February 03, 2021 07:10 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 06, 2020 08:31 ET
|
Crinetics Pharmaceuticals, Inc.
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegaly CRN04777 received Rare Pediatric Disease Designation for the...
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
September 21, 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update
December 21, 2016 17:00 ET
|
XOMA Ltd.
Up to $22 million in revenue generated through sale of royalty streams from two license agreements to HealthCare Royalty Partners, with an initial $18 million payment and up to $4 million in future...
XOMA Reports Third Quarter 2016 Achievements and Financial Results
November 09, 2016 09:00 ET
|
XOMA Ltd.
BERKELEY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and...
XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
October 19, 2016 09:00 ET
|
XOMA Ltd.
BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’s...
XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies
September 15, 2016 19:26 ET
|
XOMA Ltd.
Results Demonstrate XOMA 358 Mechanism-of-Action in Rare Endocrine ConditionsCompany Plans to Advance XOMA 358 to Multi-dose Phase 2b Studies BERKELEY, Calif., Sept. 15, 2016 (GLOBE...
XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016
September 06, 2016 09:00 ET
|
XOMA Ltd.
BERKELEY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it will host a webcast and...
XOMA to Present at the 2016 Wedbush PacGrow Healthcare Conference
August 11, 2016 14:32 ET
|
XOMA Corporation
BERKELEY, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the...
XOMA Reports Second Quarter 2016 Achievements and Financial Results
August 03, 2016 16:01 ET
|
XOMA Corporation
BERKELEY, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and...